Evidence map›Paper›PMID 30637647›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2019

Nano-multilamellar lipid vesicles (NMVs) enhance protective antibody responses against Shiga toxin (Stx2a) produced by enterohemorrhagic Escherichia coli strains (EHEC).

M J Rodrigues-Jesus, W L Fotoran, R M Cardoso, K Araki, G Wunderlich, Luís C S Ferreira

Open access · bronzeAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Topical review on nano-vaccinology: Biochemical promises and key challenges.Process biochemistry (Barking, London, England) · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

M J Rodrigues-JesusVaccine Development Laboratory, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1374, Cidade Universitária, São Paulo, SP, 05508-900, Brazil.
W L FotoranUnit for Drug Development and Plasmodium Molecular Biology, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
R M CardosoSupramolecular Chemistry and Nanotechnology Laboratory, Department of Fundamental Chemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
K ArakiSupramolecular Chemistry and Nanotechnology Laboratory, Department of Fundamental Chemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
G WunderlichUnit for Drug Development and Plasmodium Molecular Biology, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Luís C S FerreiraVaccine Development Laboratory, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1374, Cidade Universitária, São Paulo, SP, 05508-900, Brazil. lcsf@usp.br.
Universidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microlipid vesicles (MLV) have a broad spectrum of applications for the delivery of molecules, ranging from chemical compounds to proteins, in both in vitro and in vivo conditions. In the present study, we developed a new set of nanosize multilayer lipid vesicles (NMVs) containing a unique combination of lipids. The NMVs enable the adsorption of histidine-tagged proteins at the vesicle surface and were demonstrated to be suitable for the in vivo delivery of antigens. The NMVs contained a combination of neutral (DOPC) and anionic (DPPG) lipids in the inner membrane and an external layer composed of DOPC, cholesterol, and a nickel-containing lipid (DGS-NTA [Ni]). NMVs combined with a recombinant form of the B subunit of the Shiga toxin (rStx2B) produced by certain enterohemorragic Escherichia coli (EHEC) strains enhanced the immunogenicity of the antigen after parenteral administration to mice. Mice immunized with rStx2B-loaded NMVs elicited serum antibodies capable of neutralizing the toxic activities of the native toxin; this result was demonstrated both in vitro and in vivo. Taken together, these results demonstrated that the proposed NMVs represent an alternative for the delivery of antigens, including recombinant proteins, generated in different expression systems.

Indexed as

AnimalsAntibodies, BacterialAntibody FormationAntigens, BacterialDrug CarriersDrug Delivery SystemsEnterohemorrhagic Escherichia coliEscherichia coli InfectionsFemaleHumansImmunizationLipidsMiceMice, Inbred BALB CNanoparticlesShiga ToxinAntibodies, BacterialAntigens, BacterialDrug CarriersLipidsShiga ToxinDelivery systemLipids vesiclesMultilamellar vesiclesNanoparticlesShiga toxin

Identifiers

PMID30637647
PMCPMC6863297
OpenAlexW2908633853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.